{"disease":{"id":"hormone-resistant-prostate-cancer","name":"hormone resistant prostate cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06835218","title":"PROCARE - PROstate Cancer Real World Evidence Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"UroTrials Company (GmbH)","has_results":false},{"nct_id":"NCT01949337","title":"Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1311,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT03845166","title":"A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":325,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT01802346","title":"Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":130,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT01953640","title":"Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":92,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02012296","title":"Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT01519414","title":"Tivantinib in Treating Patients With Metastatic Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04516707","title":"Evaluation of Tolerance and Efficacy Retrospective Data of XOFIGO","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Institut du Cancer de Montpellier - Val d'Aurelle","has_results":false},{"nct_id":"NCT02499835","title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":true},{"nct_id":"NCT03122743","title":"Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT02312557","title":"Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":58,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":true},{"nct_id":"NCT04726332","title":"Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT01807065","title":"Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT02516670","title":"Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT01240629","title":"Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT01093183","title":"Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT02370355","title":"Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer","phase":"","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT01833208","title":"Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T","phase":"NA","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT02881242","title":"Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02215161","title":"Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT01253642","title":"Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":true},{"nct_id":"NCT03861403","title":"A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Leap Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01498978","title":"Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":true},{"nct_id":"NCT01848067","title":"Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT02853097","title":"Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients","phase":"","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT01866423","title":"Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT02844582","title":"Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"University of California, Davis","has_results":true},{"nct_id":"NCT02966587","title":"Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Washington","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}